Bio-Techne (NASDAQ:TECH) will release its earnings data before the market opens on Thursday, May 6th. Analysts expect Bio-Techne to post earnings of $1.24 per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.
Bio-Techne (NASDAQ:TECH) last released its quarterly earnings data on Monday, February 1st. The biotechnology company reported $1.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.37 by $0.25. Bio-Techne had a return on equity of 12.20% and a net margin of 32.69%. The company had revenue of $224.30 million for the quarter, compared to the consensus estimate of $206.50 million. During the same quarter last year, the business posted $1.08 EPS. Bio-Techne’s revenue for the quarter was up 21.3% on a year-over-year basis. On average, analysts expect Bio-Techne to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.
NASDAQ TECH opened at $418.22 on Wednesday. The company has a quick ratio of 4.13, a current ratio of 5.14 and a debt-to-equity ratio of 0.22. Bio-Techne has a twelve month low of $228.66 and a twelve month high of $444.83. The company has a market cap of $16.23 billion, a price-to-earnings ratio of 66.92, a price-to-earnings-growth ratio of 7.23 and a beta of 1.13. The business’s fifty day moving average is $403.62 and its 200 day moving average is $346.63.
Several research firms recently weighed in on TECH. Benchmark raised their price objective on Bio-Techne from $320.00 to $410.00 and gave the company a “buy” rating in a report on Monday, January 25th. Craig Hallum lifted their target price on Bio-Techne from $352.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, February 3rd. Citigroup lifted their target price on Bio-Techne from $310.00 to $400.00 and gave the stock a “neutral” rating in a report on Wednesday, February 3rd. Zacks Investment Research downgraded Bio-Techne from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Stephens raised Bio-Techne from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $380.00 to $425.00 in a report on Monday, March 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company’s stock. Bio-Techne presently has an average rating of “Buy” and an average price target of $375.20.
Bio-Techne Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies.
See Also: What are convertible shares?
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.